Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychoses, Manic-Depressive Clear all
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness

NCT03062267
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Mobile Interventionist
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 13, 2026, 8:54 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 13, 2026, 8:54 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 4 Interventional

Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)

NCT00453609
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Alcohol Dependence
Interventions
long-lasting injectable naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

NCT00303602
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Escondido, California • Garden Grove, California • National City, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Sep 13, 2026, 8:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

NCT01149551
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
9,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • No. Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 1 Interventional Results available

Nonconvulsive Electrotherapy: a Proof-of-concept Trial

NCT01065597
View directory record Official record
Conditions
Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
Interventions
Nonconvulsive electrotherapy
Device
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Psychiatric Advance Directives for Improved Mental Health Care

NCT00105794
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Bipolar Disorder, Stress Disorders, Post-traumatic, Psychotic Disorders
Interventions
Psychiatric Advance Directives intervention
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis

NCT01196286
View directory record Official record
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 13, 2026, 8:54 AM EDT
Completed No phase listed Observational

A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women

NCT03774641
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
Interventions
Lamictal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 13, 2026, 8:54 AM EDT
Recruiting Not applicable Interventional

Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

NCT05491538
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Interventions
Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional

Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes

NCT02188732
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression
Interventions
CBHH+AT, CBHH+SMT, CBHH
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 3 Interventional Results available

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

NCT00566735
View directory record Official record
Conditions
Major Depression, Bipolar Depression, Schizoaffective Disorder
Interventions
Razadyne, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

NCT03872596
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2008 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Not applicable Interventional Results available

Treatment to Enhance Cognition in Bipolar Disorder

NCT01470781
View directory record Official record
Conditions
Bipolar Disorder, Psychosis
Interventions
BrainWorks, Computer Control
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 13, 2026, 8:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 8:54 AM EDT